Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.40 |
| ▸ | ITGAL | P20701 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2918805 | 1.00 | ECE1 (0.42) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL18403408 | 0.84 | ECE1 (0.39) | ECE1ITGB2ICAM1ITGAL | |
| SCHEMBL8342661 | 0.84 | ECE1 (0.39) | ECE1ITGB2ICAM1ITGAL | |
| SCHEMBL13450853 | 0.82 | ECE1 (0.48) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL8337750 | 0.82 | CA2 (0.42) | CA2MAPTFOLH1 | |
| SCHEMBL6746101 | 0.82 | CA2 (0.42) | CA2MAPTFOLH1 | |
| SCHEMBL7046561 | 0.79 | KMT2A (0.47) | CA2CA1KMT2ATGFBR1FOLH1 | |
| SCHEMBL2920459 | 0.79 | KMT2A (0.47) | CA2CA1KMT2ATGFBR1FOLH1 | |
| SCHEMBL8644257 | 0.79 | ECE1 (0.30) | ECE1 | |
| SCHEMBL28337307 | 0.78 | KDM4E (0.38) | ALDH1A1MEN1KMT2ATGFBR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6114532-A | ANTICOAGULANT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-05 | — | — | US | claimed |
| EP-2982668-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | Pharmacyclics LLC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9162986-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS LLC (US) | 2015-10-20 | — | — | US | disclosed |
| EP-1569912-B1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS INC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140378453-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS LLC | 2014-12-25 | — | — | US | disclosed |
| US-8778625-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | PHARMACYLICS, INC. A DELAWARE CORPORATION (US) | 2009-02-26 | — | — | US | disclosed |
| US-7479502-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| WO-2004050637-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-6114532-A | ANTICOAGULANT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378453-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | F13B, HABP2, F7 | ECE1 1256/4885ITGB2 432/4885ICAM1 1826/4885 |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | F13B, HABP2, F7 | ECE1 1256/4885ITGB2 432/4885ICAM1 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.